Quantcast
Home > Quotes > CTSO

Cytosorbents Corporation Common Stock (CTSO) Quote & Summary Data

CTSO 
$8.98
*  
0.23
2.63%
Get CTSO Alerts
*Delayed - data as of Dec. 14, 2018 12:57 ET  -  Find a broker to begin trading CTSO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CTSO Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 8.96 / $ 8.98
1 Year Target
15
Today's High / Low
$ 8.98 / $ 8.5201
Share Volume
98,340
50 Day Avg. Daily Volume
195,275
Previous Close
$ 8.75
52 Week High / Low
$ 14.95 / $ 5.90
Market Cap
284,233,353
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.47

Intraday Chart

News for CTSO

Shares Traded

Share Volume:
98,340
50 Day Avg. Daily Volume:
195,275

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.51

Trading Range

The current last sale of $8.98 is 52.20% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.98 $ 14.95
 Low: $ 8.5201 $ 5.90

Company Description (as filed with the SEC)

We are a leader in critical care immunotherapy, investigating and commercializing our CytoSorb blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, with the goal of preventing or treating multiple organ failure in life-threatening illnesses and cardiac surgery. Organ failure is the cause of nearly half of all deaths in the intensive care unit ("ICU"), with little to improve clinical outcome. CytoSorb, our flagship product, is approved in the European Union ("EU") as a safe and effective extracorporeal cytokine filter and is designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist.  ... More ...  


Risk Grade

Where does CTSO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 8.70
Open Date:
Dec. 14, 2018
Close Price:
$ 8.75
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info